Ain K, Lee C, Holbrook K et al. Lenalidomide in distantly metastatic, rapidly progressive and radioiodine unresponsive thyroid carcinomas: preliminary results. J Clin Oncol. 2008:26(May 20 suppl). Abstract 6027.
Altekruse SF, Kosary CL, Krapcho M, et al (eds). SEER Cancer Statistics Review, 1975-2007, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2007/, based on November 2009 SEER data submission, posted to the SEER web site, 2010. Accessed June 3, 2011.
American Cancer Society. Cancer Facts & Figures 2011. Atlanta, Ga: American Cancer Society; 2011.
American Cancer Society. Cancer Facts & Figures 2012. Atlanta, Ga: American Cancer Society; 2012.
American Joint Committee on Cancer. Thyroid. In: AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2010:87−92.
American Thyroid Association Guidelines Task Force, Kloos RT, Eng C, Evans DB, et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid. 2009;19:565−612.
American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167−1214.
Baudin E, Schlumberger M. New therapeutic approaches for metastatic thyroid carcinoma. Lancet Oncol. 2007;8:148−156.
Bible KC, Suman VJ, Molina JR, et al. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: Results of a phase 2 consortium study. Lancet Oncol. 2010;11:962−972.
Carling T, Udelsman R. Thyroid tumors. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 8th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2008:1663−1682.
Carr LL, Mankoff DA, Goulart BH, et al. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res. 2010;16:5260−5268.
Cohen E, Rosen L, Vokes E et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: Results from a phase II study. J Clin Oncol. 2008;26:4708−4713.
Fagin JA. Challenging dogma in thyroid cancer molecular genetics — role of RET/PTC and BRAF in tumor initiation. J Clin Endocrinol Metab. 2004;89:4280−4284.
Frates MC, Benson CB, Charboneau IW, et al. Management of thyroid nodules detected in US: Society of Radiologists in Ultrasound consensus conference statement. Radiology 2005;237:794−800.
Gupta-AbramsonV, Troxel A, Nellore A, et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol. 2008:26:4714−4719.
Kloos RT, Ringel MD, Knopp MV, et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol. 2009;27:1675−1684.
Kurzrock R, Sherman SI, Ball DW, et al. Activity of XL184 (cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol. 2011 May 23. [Epub ahead of print]
Lal G, D'Orosio T, McDougall R, Wiegel RJ. Cancer of the endocrine system. In: Abeloff MD, Armitage JO, Niederhuber JE, Kastan MB, McKenna WG, eds. Abeloff's Clinical Oncology. 4th ed. Philadelphia, Pa: Elsevier; 2008:1271−1305.
National Cancer Institute. Physician Data Query (PDQ). Thyroid Cancer Treatment. 2011. Accessed at www.cancer.gov/cancertopics/pdq/treatment/thyroid/healthprofessional on June 3, 2011.
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Thyroid Carcinoma. V.2.2011. Accessed at www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf on June 3, 2011.
Sherman SI, Wirth LJ, Droz J-P, et al. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med. 2008;359:31−42
Schlumberger MJ, Elisei R, Bastholt L, et al. Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol. 2009;27:3794−3801.
Vaisman A, Orlov S, Yip J, et al. Application of post-surgical stimulated thyroglobulin for radioiodine remnant ablation selection in low-risk papillary thyroid carcinoma. Head Neck. 2010;32:689−698.
Wells SA Jr, Gosnell JE, Gagel RF, et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol. 2010;28:767−772.
Feedback
